PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) announced that it will present new clinical and preclinical data at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting, taking place November 7–9, 2025, in National Harbor, Maryland. The company’s two poster presentations will highlight its growing pipeline of bispecific T cell engagers (TCEs) targeting difficult-to-treat solid tumors.
The first presentation will feature a Trial in Progress poster for the company’s Phase 1 study of CT-95, a Mesothelin x CD3 bispecific T cell engager designed to harness the immune system against tumors expressing mesothelin. The second will share preclinical efficacy, safety, and pharmacokinetic data for CT-202, a Nectin-4 x CD3 bispecific T cell engager designed for selective activity within the tumor microenvironment.
Poster Presentation Details
- CT-202: A Dual pH-Dependent Nectin-4 x CD3 Bispecific T Cell Engager
- Date & Time: Friday, November 7, 2025, 10:00 a.m. ET
- Abstract Number: 963
- Location: Prince George ABC Exhibit Halls
- Trial in Progress: A Phase 1, First-in-Human Study of CT-95, a Mesothelin (MSLN)-Directed Bispecific T Cell Engager (TCE) in Subjects with Advanced Solid Tumors
- Date & Time: Saturday, November 8, 2025, 10:00 a.m. ET
- Abstract Number: 586
- Location: Prince George ABC Exhibit Halls
CT-95 is a fully humanized bispecific antibody designed to direct T cells toward mesothelin-expressing cancer cells. Mesothelin is overexpressed in roughly 30% of cancers, but drug development has been complicated by “shed” mesothelin fragments that can act as decoys. CT-95’s design seeks to overcome this challenge through moderate affinity but high avidity for membrane-bound mesothelin, minimizing interference from shed fragments. The Phase 1 trial (NCT06756035) is enrolling patients in the United States.
CT-202, meanwhile, targets Nectin-4 — a clinically validated tumor-associated protein expressed in cancers such as bladder, colorectal, lung, and breast. Unlike traditional antibody-drug conjugates that have been linked to neuropathy and rash, CT-202 is engineered for pH-dependent activation within the acidic tumor microenvironment, potentially improving selectivity and tolerability.
The upcoming SITC presentations mark a key milestone for Context Therapeutics as it advances a new generation of targeted immunotherapies designed to enhance efficacy while reducing off-target effects in solid tumors.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.